{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:19:51Z","timestamp":1771928391152,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the predictive value of peripheral blood immune markers for progression to castration-resistant prostate cancer (CRPC) in prostate cancer (PCa) patients undergoing endocrine therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 106 PCa patients treated with endocrine therapy between 2021 and 2024. Peripheral blood immune parameters were compared between patients who did and did not experience progression to CRPC (progression and stable groups, respectively). The identified independent predictors of CRPC were then used to construct a nomogram for the identification of high-risk patients for early intervention. Internal validation was performed using the bootstrap method with 1000 resamples. Nomogram performance was evaluated by receiver operating characteristic curve, calibration curve, and decision curve analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Univariate analysis showed significant differences (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05) in prostate-specific antigen level, Gleason score, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio, systemic immune inflammation index (SII), and pan-immune inflammation value (PIV), CD4+\/CD8+ T cell ratio, and T4 stage between the progression and stable groups. Multivariate analysis further identified the PLR, SII, CD4+\/CD8+ T cell ratio, and T4 stage as independent risk factors for CRPC development. The developed predictive model demonstrated strong predictive performance (area under the curve =0.934, Hosmer\u2013Lemeshow\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt;0.05). The c-index for internal validation was 0.914, further confirming the predictive performance of the model. Employing clinically optimized thresholds, survival analysis confirmed that a PLR \u2265140, SII \u2265520, and CD4+\/CD8+ T cell ratio &amp;lt;1.6 could significantly predict the 2-year CRPC risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PLR, SII, CD4+\/CD8+ T cell ratio, and T4 tumor stage are independent risk factors for CRPC progression within 2 years of endocrine therapy. The survival prediction model based on these factors offers good predictive efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1696687","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:16:12Z","timestamp":1770009372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of peripheral blood immune markers for castration-resistant prostate cancer development after endocrine therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Fengshan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medicine, Graduate School, Henan University","place":["Kaifeng, China"]},{"name":"Department of Urology, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Urology, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanlan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology and Wuxi School of Medicine, Jiangnan University Medical Center","place":["Wuxi, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Urology, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S117176","article-title":"Androgen deprivation therapy as backbone therapy in the management of prostate cancer","volume":"9","author":"Merseburger","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e7823","DOI":"10.1097\/md.0000000000007823","article-title":"Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study","volume":"96","author":"Ji","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13253","article-title":"Prognostic significance of time to castration resistance in patients with metastatic castration-sensitive prostate cancer","volume":"39","author":"Miyake","year":"2019","journal-title":"Anticancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2236-4","article-title":"The impact of time to metastasis on overall survival in patients with prostate cancer","volume":"36","author":"Frees","year":"2018","journal-title":"World J Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12935-020-1094-5","article-title":"Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0432-4","article-title":"Pretreatment neutrophil\/lymphocyte ratio is superior to platelet\/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients","volume":"30","author":"Azab","year":"2013","journal-title":"Med Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-350","article-title":"Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-12-58","article-title":"Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma","volume":"12","author":"Feng","year":"2014","journal-title":"World J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/1354750x.2014.926567","article-title":"The role of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer","volume":"19","author":"Jiang","year":"2014","journal-title":"Biomarkers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24061","article-title":"Preoperative neutrophil to lymphocyte ratio predicts survival in patients with T1-2N0 colorectal cancer","volume":"112","author":"Shin","year":"2015","journal-title":"J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci80007","article-title":"Immunity, inflammation, and cancer: an eternal fight between good and evil","volume":"125","author":"Shalapour","year":"2015","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3390\/cancers17091556","article-title":"A multiparametric MRI and baseline-clinical-feature-based dense multimodal fusion artificial intelligence (MFAI) model to predict castration-resistant prostate cancer progression","volume":"17","author":"He","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2022.01.017","article-title":"A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers","volume":"29","author":"Merae Alshahrani","year":"2022","journal-title":"Saudi J Biol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00618-2","article-title":"Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer","volume":"26","author":"Wang","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3390\/cancers15102847","article-title":"Practical utility of liquid biopsies for evaluating genomic alterations in castration-resistant prostate cancer","volume":"15","author":"Jeong","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1427068","article-title":"CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer","volume":"18","author":"Bastos","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22024","DOI":"10.1038\/s41598-022-24426-9","article-title":"Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202102_24834","article-title":"Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis","volume":"25","author":"Wang","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724443","article-title":"PIV and PILE score at baseline predict clinical outcome of anti-PD-1\/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00819-0","article-title":"The pan-immune-inflammation value in patients with metastatic melanoma receiving first-line therapy","volume":"16","author":"Fuc\u00e0","year":"2021","journal-title":"Target Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1245\/s10434-019-08094-0","article-title":"Prognostic value of the systemic immune-inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer","volume":"27","author":"Murthy","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5653-x","article-title":"Prognostic significance of vas deferens invasion after radical prostatectomy in patients with pathological stage T3b prostate cancer","volume":"24","author":"Jang","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2016.12.002","article-title":"Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up","volume":"26","author":"Heering","year":"2017","journal-title":"Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01716-8","article-title":"Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy","volume":"25","author":"Hashimoto","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2015.16.15.6407","article-title":"Predictive value of the platelet-to-lymphocyte ratio in diagnosis of prostate cancer","volume":"16","author":"Yuksel","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0209-3","article-title":"Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis","volume":"23","author":"Guan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1991591","article-title":"Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis","volume":"53","author":"Li","year":"2021","journal-title":"Ann Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e23883","DOI":"10.1002\/jcla.23883","article-title":"The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence","volume":"35","author":"Zhao","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann Afr Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12967-023-03924-y","article-title":"Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis","volume":"21","author":"Meng","year":"2023","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02801-y","article-title":"iPad-assisted percutaneous nephrolithotomy (PCNL): a matched pair analysis compared to standard PCNL","volume":"38","author":"Rassweiler-Seyfried","year":"2020","journal-title":"World J Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.164","article-title":"CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer","volume":"26","author":"Davidsson","year":"2013","journal-title":"Mod Pathol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.14218\/CSP.2024.00029","article-title":"Exosomes: A promising tool for liquid biopsy in prostate cancer","volume":"4","author":"Qiu","year":"2025","journal-title":"Cancer Screening Prev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/cells14221804","article-title":"Precision oncology: current landscape, emerging trends, challenges, and future perspectives","volume":"14","author":"Qiao","year":"2025","journal-title":"Cells"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1696687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:28:33Z","timestamp":1771925313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1696687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1696687"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1696687","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"article-number":"1696687"}}